PURPOSE: Recently, a GGGGCC hexanucleotide repeat expansion in the C9ORF72 gene, located on chromosome 9p21 has been demonstrated to be the commonest cause of familial amyotrophic lateral sclerosis (ALS) and to account for 5 to 10 % of apparently sporadic ALS. Relatively little is known about the brain metabolism profile of patients carrying the expansion. Our aim was to identify the [(18)F]FDG PET profile in ALS patients with the C9ORF72 expansion (C9ORF72-ALS). METHODS: Fifteen C9ORF72-ALS patients were compared with 12 patients with ALS and comorbid frontotemporal dementia (FTD) without the C9ORF72 expansion (ALS-FTD) and 30 cognitively normal patients with ALS without mutations of ALS-related genes (sALS). The three groups were then cross-matched to 40 neurologically normal controls. All patients underwent FDG PET within 4 months of diagnosis. RESULTS: The C9ORF72-ALS patients compared with the sALS patients showed significant hypometabolism in the anterior and posterior cingulate cortex, insula, caudate and thalamus, the left frontal and superior temporal cortex, and hypermetabolism in the midbrain, bilateral occipital cortex, globus pallidus and left inferior temporal cortex. The ALS-FTD patients compared with the sALS patients showed more limited hypometabolic areas, including the orbitofrontal, prefrontal, anterior cingulate and insular cortex, and hypermetabolic areas, including the bilateral occipital cortex, the left precentral and postcentral cortex and superior temporal gyrus. The C9ORF72-ALS patients compared with the ALS-FTD patients showed hypometabolism in the left temporal cortex. CONCLUSION: ALS patients with the C9ORF72 hexanucleotide repeat expansion had a more widespread central nervous system involvement than ALS patients without genetic mutations, with or without comorbid FTD, consistent with their more severe clinical picture.
PURPOSE: Recently, a GGGGCC hexanucleotide repeat expansion in the C9ORF72 gene, located on chromosome 9p21 has been demonstrated to be the commonest cause of familial amyotrophic lateral sclerosis (ALS) and to account for 5 to 10 % of apparently sporadic ALS. Relatively little is known about the brain metabolism profile of patients carrying the expansion. Our aim was to identify the [(18)F]FDG PET profile in ALS patients with the C9ORF72 expansion (C9ORF72-ALS). METHODS: Fifteen C9ORF72-ALS patients were compared with 12 patients with ALS and comorbid frontotemporal dementia (FTD) without the C9ORF72 expansion (ALS-FTD) and 30 cognitively normal patients with ALS without mutations of ALS-related genes (sALS). The three groups were then cross-matched to 40 neurologically normal controls. All patients underwent FDG PET within 4 months of diagnosis. RESULTS: The C9ORF72-ALS patients compared with the sALS patients showed significant hypometabolism in the anterior and posterior cingulate cortex, insula, caudate and thalamus, the left frontal and superior temporal cortex, and hypermetabolism in the midbrain, bilateral occipital cortex, globus pallidus and left inferior temporal cortex. The ALS-FTD patients compared with the sALS patients showed more limited hypometabolic areas, including the orbitofrontal, prefrontal, anterior cingulate and insular cortex, and hypermetabolic areas, including the bilateral occipital cortex, the left precentral and postcentral cortex and superior temporal gyrus. The C9ORF72-ALS patients compared with the ALS-FTD patients showed hypometabolism in the left temporal cortex. CONCLUSION: ALS patients with the C9ORF72 hexanucleotide repeat expansion had a more widespread central nervous system involvement than ALS patients without genetic mutations, with or without comorbid FTD, consistent with their more severe clinical picture.
Authors: Mariely DeJesus-Hernandez; Ian R Mackenzie; Bradley F Boeve; Adam L Boxer; Matt Baker; Nicola J Rutherford; Alexandra M Nicholson; NiCole A Finch; Heather Flynn; Jennifer Adamson; Naomi Kouri; Aleksandra Wojtas; Pheth Sengdy; Ging-Yuek R Hsiung; Anna Karydas; William W Seeley; Keith A Josephs; Giovanni Coppola; Daniel H Geschwind; Zbigniew K Wszolek; Howard Feldman; David S Knopman; Ronald C Petersen; Bruce L Miller; Dennis W Dickson; Kevin B Boylan; Neill R Graff-Radford; Rosa Rademakers Journal: Neuron Date: 2011-09-21 Impact factor: 17.173
Authors: Anna Caroli; Annapaola Prestia; Kewei Chen; Napatkamon Ayutyanont; Susan M Landau; Cindee M Madison; Cathleen Haense; Karl Herholz; Flavio Nobili; Eric M Reiman; William J Jagust; Giovanni B Frisoni Journal: J Nucl Med Date: 2012-02-17 Impact factor: 10.057
Authors: Adam L Boxer; Ian R Mackenzie; Bradley F Boeve; Matthew Baker; William W Seeley; Richard Crook; Howard Feldman; Ging-Yuek R Hsiung; Nicola Rutherford; Victor Laluz; Jennifer Whitwell; Dean Foti; Eric McDade; Jennifer Molano; Anna Karydas; Aleksandra Wojtas; Jill Goldman; Jacob Mirsky; Pheth Sengdy; Stephen Dearmond; Bruce L Miller; Rosa Rademakers Journal: J Neurol Neurosurg Psychiatry Date: 2010-06-20 Impact factor: 10.154
Authors: Matthew C Kiernan; Steve Vucic; Benjamin C Cheah; Martin R Turner; Andrew Eisen; Orla Hardiman; James R Burrell; Margaret C Zoing Journal: Lancet Date: 2011-02-04 Impact factor: 79.321
Authors: V Ibáñez; P Pietrini; G E Alexander; M L Furey; D Teichberg; J C Rajapakse; S I Rapoport; M B Schapiro; B Horwitz Journal: Neurology Date: 1998-06 Impact factor: 9.910
Authors: Michael J Strong; Gloria M Grace; Morris Freedman; Cathy Lomen-Hoerth; Susan Woolley; Laura H Goldstein; Jennifer Murphy; Christen Shoesmith; Jeffery Rosenfeld; P Nigel Leigh; Lucie Bruijn; Paul Ince; Denise Figlewicz Journal: Amyotroph Lateral Scler Date: 2009-06
Authors: M R Turner; A Cagnin; F E Turkheimer; C C J Miller; C E Shaw; D J Brooks; P N Leigh; R B Banati Journal: Neurobiol Dis Date: 2004-04 Impact factor: 5.996
Authors: Stacey Li Hi Shing; Mary Clare McKenna; We Fong Siah; Rangariroyashe H Chipika; Orla Hardiman; Peter Bede Journal: Brain Imaging Behav Date: 2021-01-05 Impact factor: 3.978
Authors: Vincent Picher-Martel; Paul N Valdmanis; Peter V Gould; Jean-Pierre Julien; Nicolas Dupré Journal: Acta Neuropathol Commun Date: 2016-07-11 Impact factor: 7.801
Authors: Stefanie M A Willekens; Donatienne Van Weehaeghe; Philip Van Damme; Koen Van Laere Journal: Eur J Nucl Med Mol Imaging Date: 2016-12-08 Impact factor: 9.236
Authors: Pilar M Ferraro; Charles Jester; Christopher A Olm; Katerina Placek; Federica Agosta; Lauren Elman; Leo McCluskey; David J Irwin; John A Detre; Massimo Filippi; Murray Grossman; Corey T McMillan Journal: Neurobiol Aging Date: 2018-04-17 Impact factor: 4.673
Authors: Jordi A Matías-Guiu; Vanesa Pytel; María Nieves Cabrera-Martín; Lucía Galán; María Valles-Salgado; Antonio Guerrero; Teresa Moreno-Ramos; Jorge Matías-Guiu; José Luis Carreras Journal: Eur J Nucl Med Mol Imaging Date: 2016-06-04 Impact factor: 9.236